Influence of Onset to Imaging Time on Radiological Thrombus Characteristics in Acute Ischemic Stroke

Thrombus perviousness in acute ischemic stroke: a scoping review of methodology, predictive value, and future perspectives

PURPOSE

Thrombus perviousness, depicting the interaction of occlusive clot with contrast media as measured with computed tomography (CT) is a relatively new imaging biomarker in acute ischemic stroke (AIS). This approach holds the potential to tailor revascularization strategies and post-interventional treatments, thereby enhancing functional outcomes. However, its predictive value is not yet conclusive despite its association with several clinical parameters.  METHODS: This scoping review provides a comprehensive overview of 51 articles that explore this issue. It focuses on the analysis of applied methodology in measuring perviousness, the predictive value of perviousness based on available data, and the future perspectives and potentials this biomarker may have in AIS imaging.  RESULTS: Although some data are contradictory, in the vast majority of published studies, pervious thrombi were easier to remove with mechanical thrombectomy, responded better to thrombolytic treatment and showed better functional outcome than impervious thrombi. The methodology of measuring perviousness is not yet standardized, which may lead to inconsistency in the findings. New data on time-resolved (dynamic) perviousness show more promising results and refined characterization of occlusive thrombi in AIS.

Computed Tomography Angiography-Based Thrombus Radiomics for Predicting the Time Since Stroke Onset

RATIONALE AND OBJECTIVES

The measurement of the time since stroke onset (TSS) is crucial for decision-making in the treatment of acute ischemic stroke (AIS). This study assessed the utility of computed tomography angiography (CTA) radiomics features (RFs) to estimate TSS.

MATERIALS AND METHODS

A total of 221 patients with AIS were enrolled in this retrospective study and were divided into a training group (n = 154) and a test group (n = 67). Thrombi in CTA images were manually outlined using ITK-SNAP. Images were aligned, normalized, and pre-processed to extract RFs. The TSS was calculated as the time from stroke onset to CTA completion. The patients were classified into two groups according to estimated TSS: ≤4.5 and >4.5 hours. A total of 944 RFs were extracted from CTA images. Clinical factors associated with TSS were identified using multivariate logistic regression, and a combined model (clinical data and RFs) was constructed. The predictive value of the models was assessed by the area under the receiver operating characteristic curve (AUC). The performance of the models was compared using the DeLong test, and clinical utility was evaluated by decision curve analysis.

RESULTS

The AUC of the radiomics model was 0.803 (95% confidence interval [CI]: 0.733-0.873) and 0.803 (95% CI: 0.698-0.908) in the training and test cohorts, respectively. The AUC of the combined model (containing data on age, diabetes, and atrial fibrillation) in the training and test sets was 0.813 (95% CI: 0.750-0.889) and 0.803 (95% CI: 0.699-0.907), respectively. The DeLong test showed no significant difference between the radiomics and combined models. Decision curve analysis showed that both models had clinical utility.

CONCLUSION

CTA-based thrombus radiomics can estimate TSS in patients with AIS. The addition of clinical data to the model does not improve predictive performance.

Spatial heterogeneity of occlusive thrombus in acute ischemic stroke: A systematic review

Following the advent of mechanical thrombectomy, occlusive clots in ischemic stroke have been amply characterized using conventional histopathology. Many studies have investigated the compositional variability of thrombi and the consequences of thrombus composition on treatment response. More recent evidence has emerged about the spatial heterogeneity of the clot or the preferential distribution of its components and compact nature. Here we review this emerging body of evidence, discuss its potential clinical implications, and propose the development of adequate characterization techniques.

Associations between early ischemic signs on non-contrast CT and time since acute ischemic stroke onset: A scoping review

PURPOSE

Onset to imaging (OTI) time is a crucial factor in determining treatment eligibility for acute ischemic stroke patients, since the treatments are time-dependent. Patients with an unknown OTI time are often excluded from treatment, or advanced imaging is needed, which is not widely and readily available. As non-contrast CT (NCCT) is part of the standard stroke protocol, estimating OTI time using only NCCT would be valuable for patients with an unknown OTI time. Early ischemic signs (EISs) visible on NCCT might be fit for this purpose if an association between these signs and OTI time exists. This scoping review aims to provide an overview of the literature that associated OTI time with qualitative or quantitative EISs, including the hyperdense artery sign (HAS), decrease in grey matter-white matter differentiation, hypodensity, and mass effect.

METHOD

The prevalence of the EISs at specific OTI times is assessed, and previously presented associations between the EISs and OTI time are reported.

RESULTS

The EIS prevalence varied between the studies. The HAS prevalence decreased after 6 h since onset. The hypodensity prevalence increased with increasing OTI time. Studies quantifying the extent of hypodensity could distinguish patients within and beyond treatment time windows, indicating its potential to estimate OTI time. Finally, mass effect prevalence was seen more often at later OTI times.

CONCLUSIONS

It is concluded that, despite the high prevalence variability between studies, some associations between EISs and OTI time can be observed. These are potentially valuable in estimating OTI time and supporting treatment decisions.

Recent Advances in Nanomaterials for Diagnosis, Treatments, and Neurorestoration in Ischemic Stroke

Stroke is a major public health issue, corresponding to the second cause of mortality and the first cause of severe disability. Ischemic stroke is the most common type of stroke, accounting for 87% of all strokes, where early detection and clinical intervention are well known to decrease its morbidity and mortality. However, the diagnosis of ischemic stroke has been limited to the late stages, and its therapeutic window is too narrow to provide rational and effective treatment. In addition, clinical thrombolytics suffer from a short half-life, inactivation, allergic reactions, and non-specific tissue targeting. Another problem is the limited ability of current neuroprotective agents to promote recovery of the ischemic brain tissue after stroke, which contributes to the progressive and irreversible nature of ischemic stroke and also the severity of the outcome. Fortunately, because of biomaterials’ inherent biochemical and biophysical properties, including biocompatibility, biodegradability, renewability, nontoxicity, long blood circulation time, and targeting ability. Utilization of them has been pursued as an innovative and promising strategy to tackle these challenges. In this review, special emphasis will be placed on the recent advances in the study of nanomaterials for the diagnosis and therapy of ischemic stroke. Meanwhile, nanomaterials provide much promise for neural tissue salvage and regeneration in brain ischemia, which is also highlighted.

Factors That Influence Susceptibility Vessel Sign in Patients With Acute Stroke Referred for Mechanical Thrombectomy

Background and Purpose

The presence of a Susceptibility Vessel Sign (SVS) in the acute phase of proximal occlusion ischemic stroke indicates the presence of deoxyhemoglobin in the thrombus. Thrombi composition changes over time. The aim of this study was to investigate whether the absence of SVS is associated with a shorter symptom onset to imaging time.

Methods

We retrospectively analyzed all patients referred for mechanical thrombectomy at Besançon University Hospital between 1 January 2015 and 31 December 2020 for whom readable T2^*-weighted imaging was available. We compared patient characteristics according to the presence or absence of an SVS. We also studied the subgroup for whom the exact symptom onset time was known. We performed a univariate statistical analysis, then a multivariate analysis on the variables that were statistically significant in the univariate analysis.

Results

Of the 389 patients included, 309 (79.4%) were SVS+. We found no significant relationship between SVS– and the time between symptom onset and imaging in the whole cohort. In the multivariate analysis, SVS– was associated with anticoagulant treatment (p < 0.01), and SVS+ with age (p = 0.023) and carotid terminus occlusion (p = 0.042). In the known symptom onset subgroup, SVS– was significantly associated with a shorter symptom onset -imaging time (p < 0.001), and this was confirmed in the multivariate analysis (p = 0.011; OR 0.911; 95% CI [0.844; 0.972]).

Conclusion

In the acute phase of proximal occlusion ischemic stroke, absence of SVS was associated with a shorter symptom onset–imaging time for patients with a known symptom onset time.